Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Transfus Med ; 31(3): 155-159, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-807793

ABSTRACT

OBJECTIVE: The COVID-19 epidemic has caused a significant global social and economic impact since December 2019. The objective of this study was to demonstrate the emergency response of a Chinese blood centre on maintaining both the safety and the sufficiency of blood supply during large, emerging, infectious epidemics. MATERIALS AND METHODS: Early on in the outbreak of COVID-19, the Chengdu Blood Center developed strategies and implemented a series of measures, including enhanced recruitment efforts, addition of new donation deferral criteria and notification after donation, optimisation of donor experience, development and implementation of a new coronavirus nucleic acid detection technology platform for blood screening and screening all donations for SARS-CoV-2 RNA to maximumly protect the safety of blood supply during a time of unclear risk. RESULTS: Starting on February 20, the immediate satisfaction rate of blood product orders in Chengdu city's clinical settings reached 100%, and there was no case of blood transfusion infection. CONCLUSION: The recent experience during the outbreak of SARS-CoV-2 reminded us that improvement in the areas of national and international collaborative programmes for dealing with blood availability and safety concerns during early stages of a disaster and regional and national mechanisms for timely communication with the general public on behalf of blood services should help to better prepare us for future disasters.


Subject(s)
Blood Banks/supply & distribution , Blood Banks/statistics & numerical data , Blood Donors/statistics & numerical data , COVID-19/epidemiology , Emergency Treatment/statistics & numerical data , SARS-CoV-2 , Adolescent , Adult , Blood Safety/statistics & numerical data , Blood Transfusion/statistics & numerical data , COVID-19/therapy , China/epidemiology , Donor Selection , Humans , Immunization, Passive , Pandemics , Plasma , Young Adult , COVID-19 Serotherapy
SELECTION OF CITATIONS
SEARCH DETAIL